Breast Cancer Coverage From Every Angle
Advertisement
Advertisement

Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Cancer Patients

Investigators seeking to extend the chemotherapy-free period for women with metastatic hormone receptor–positive, HER2-negative breast cancer continue to explore attractive treatment options for this tumor subtype. Everolimus plus exemestane is an approved regimen for patients whose disease progresses on first-line endocrine therapy alone, and the more recent approval of the CDK 4/6 inhibitor palbociclib plus letrozole or fulvestrant also can postpone the necessity for chemotherapy. Now, a report from the 2016 San Antonio Breast Cancer Symposium suggests that the combination of everolimus and fulvestrant may also be useful as second-line treatment, which again delays the switch to chemotherapy in these patients with metastatic disease.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.